白蛋白紫杉醇联合放疗治疗局部晚期食管癌的疗效

刘金凤; 王章桂; 崔珍

doi:10.16766/j.cnki.issn.1674-4152.002090

白蛋白紫杉醇联合放疗治疗局部晚期食管癌的疗效

doi: 10.16766/j.cnki.issn.1674-4152.002090

1.
安徽省第二人民医院放射治疗科，安徽合肥 230041
2.
蚌埠医学院第一附属医院放射治疗科，安徽蚌埠 233004

基金项目:

安徽省教育厅科研基金项目 KJ2019A0357

详细信息

通讯作者:
王章桂，E-mail：450944741@qq.com

中图分类号: R735.1 R730.58
计量
- 文章访问数: 160
- HTML全文浏览量: 217
- PDF下载量: 4
- 被引次数: 0
出版历程
- 收稿日期: 2020-11-21
- 网络出版日期: 2022-02-15

Efficacy analysis of albumin paclitaxel and radiotherapy in locally advanced oesophageal cancer

1.
Department of Radiation Therapy, the Second People's Hospital of Anhui Province, Hefei, Anhui 230041, China

摘要

摘要: 目的同步放化疗是局部晚期食管癌不能手术的首选治疗，紫杉类化疗药物联合顺铂同步放化疗现已广泛应用于临床，本研究目的为观察白蛋白紫杉醇联合顺铂同步放化疗治疗局部晚期食管癌的安全性及临床疗效。方法回顾性分析2018年1月—2019年7月安徽省第二人民医院放射治疗科收治的局部晚期食管癌患者共计45例，均行根治性同步放化疗，其中22例行白蛋白紫杉醇+顺铂(试验组)同步化疗及23例行顺铂(对照组)同步放化疗，同步放化疗治疗结束后3个月行胸部CT、钡餐等检查评价临床疗效，并电话随访患者1年无疾病生存率。结果白蛋白紫杉醇+顺铂同步放化疗组客观缓解率(objective response rate, ORR)为77.3%，顺铂同步放化疗组客观缓解率为47.8%，2组差异无统计学意义(P < 0.05)；白蛋白紫杉醇+顺铂同步放化疗组随访1年的总生存率(overall survival rate, OS, 90.2%)高于顺铂同步放化疗组(78.0%)，虽然2组患者不良反应发生率比较白细胞减少及周围神经损伤差异有统计学意义(P < 0.05)，但大多为1~2级反应，患者可耐受。结论局部晚期食管癌患者给予白蛋白紫杉醇联合顺铂同步放化疗治疗，临床疗效较好，1年生存率较高，不良反应可耐受。
- 白蛋白紫杉醇 /
- 放疗 /
- 局部晚期食管癌 /
- 疗效
Abstract: Objective Synchronous radiotherapy and chemotherapy is the first choice for inoperable treatment of locally advanced oesophageal cancer. Taxane chemotherapy drugs combined with cisplatin and concurrent radiotherapy and chemotherapy have been widely used in clinical practice. Therefore, the purpose of this study is to observe the safety and clinical efficacy of albumin paclitaxel combined with cisplatin and concurrent radiotherapy and chemotherapy in locally advanced oesophageal cancer. Methods Retrospective analysis was performed on a total of 45 patients with locally advanced esophageal cancer admitted to the Department of Radiotherapy of the Second People's Hospital of Anhui Province from January 2018 to July 2019. All received radical concurrent radiotherapy and chemotherapy, Among them, 22 patients received concurrent chemotherapy with albumin paclitaxel and cisplatin (experimental group) and 23 patients received concurrent chemoradiotherapy with cisplatin (control group), Three months after the end of concurrent radiotherapy and chemotherapy, chest CT, barium meal and other examinations were performed to evaluate the clinical efficacy, and the patients were followed up by telephone for a 1-year disease-free survival rate. Results The objective response rate (ORR) of the albumin paclitaxel+cisplatin concurrent radiotherapy and chemotherapy group was 77.3%, and the ORR of the cisplatin concurrent radiotherapy and chemotherapy group was 47.8%. The difference between the two groups was not statistically significant (P < 0.05). The overall survival rate (90.2%) of the albumin paclitaxel+cisplatin concurrent radiotherapy and chemotherapy group was higher than that of the cisplatin concurrent radiotherapy group (78.0%). A statistically significant difference was observed in peripheral nerve injury (P < 0.05), but most of them were grade 1 to 2 reactions, which could be tolerated by patients. Conclusion The clinical effect of albumin paclitaxel combined with cisplatin concurrent radiotherapy and chemotherapy on locally advanced oesophageal cancer is good, the 1-year survival rate is high, and the adverse reactions are tolerable.
- Albumin paclitaxel /
- Radiotherapy /
- Locally advanced oesophageal cancer /
- Curative effect

HTML全文

图 1 2组局部晚期食管癌患者总生存曲线图

下载: 全尺寸图片幻灯片

表 1 2组局部晚期食管癌患者临床疗效比较

组别	例数	CR(例)	PR(例)	SD(例)	PD(例)	ORR(%)
试验组	22	6	11	4	1	77.3(17/22)
对照组	23	3	8	9	3	47.8(11/23)
注：2组ORR比较，χ²=4.148，P=0.042。

下载: 导出CSV

表 2 2组局部晚期食管癌患者不良反应发生率比较(例)

组别	例数	放射性食管炎		恶心呕吐		白细胞减少		血小板减少		周围神经损伤		皮疹
组别	例数	1~2级	3~4级	1~2级	3~4级	1~2级	3~4级	1~2级	3~4级	1~2级	3~4级	1~2级	3~4级
试验组	22	10	1	13	4	13	3	8	1	11	1	7	1
对照组	23	9	1	11	5	7	1	7	0	5	0	5	0
χ²值		0.192		0.342		6.505		0.218		5.148		1.171
P值		0.661		0.559		0.011		0.641		0.023		0.279

下载: 导出CSV

参考文献(17)

[1]	CHEN W, ZHENG R, BAADE P D, et al. Cancerstatistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. doi: 10.3322/caac.21338
[2]	戴婷婷, 王万伟, 仝宇梭, 等. 多西他赛联合顺铂同步放化疗和单纯放疗治疗老年非手术食管鳞癌的临床疗效分析[J]. 实用癌症杂志, 2019, 34(3): 417-420. doi: 10.3969/j.issn.1001-5930.2019.03.019
[3]	TU C C, HSU P K. The frontline of esophageal cancer treatment: Questions to be asked and answered[J]. Ann Transl Med, 2018, 6(4): 83. doi: 10.21037/atm.2017.10.31
[4]	林展, 梁雷锋, 覃金莲, 等. 局部晚期食管癌根治性同步放化疗放疗剂量60 Gy对比50.4 Gy的临床研究[J]. 名医, 2020(4): 85. https://www.cnki.com.cn/Article/CJFDTOTAL-MGYI202004077.htm
[5]	COOPER J S, GUO M D, HERSKOVIC A, et al. Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01)[J]. JAMA, 1999, 281(17): 1623-1627. http://europepmc.org/abstract/med/10235156
[6]	JING W, YAN W W, LIU Y G, et al. Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma[J]. Cancer Biol Thera, 2019, 20(5): 1121-1126. http://www.onacademic.com/detail/journal_1000042291111099_71a9.html
[7]	SUNTHARALINGAM M, WINTER K, ILSON D, et al. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: The NRG oncology RTOG0436 phase 3 randomized clinical trial[J]. JAMA Oncology, 2017, 3(11): 1520-1528. doi: 10.1001/jamaoncol.2017.1598
[8]	CHEN Y, YE J, ZHU Z, et al. Comparing paclitaxel plus fluorouracil versus cisplatin plus fluorouracil in chemoradiotherapy forlocally advanced esophageal squamous cell cancer: A randomized, multicenter, phase Ⅲ clinical trial[J]. J Clin Oncol, 2019, 37(20): 1695-1703. doi: 10.1200/JCO.18.02122
[9]	DAS M, SAIKIA B J, SHARMA S K, et al. p16 hypermethylation: A biomarker for increased esophageal cancer susceptibility in high incidence region of North East India[J]. Tumor Biology, 2015, 36(3): 1627-1642. doi: 10.1007/s13277-014-2762-7
[10]	JOHN T A, VOGEL S M, TIRUPPATHI C, et al. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelia lmonolayer[J]. Am J Physiol Lung Cell Mol Physiol, 2003, 284(1): L187-196. doi: 10.1152/ajplung.00152.2002
[11]	范丽萍, 焦园园, 郭子寒, 等. 白蛋白结合型紫杉醇与溶剂型紫杉醇治疗转移性乳腺癌的最小成本分析[J]. 中国药房, 2016, 27(32): 4477-4479. doi: 10.6039/j.issn.1001-0408.2016.32.04
[12]	张惠茹. 白蛋白结合型紫杉醇治疗晚期乳腺癌的疗效及安全性[J]. 中国实用医药, 2016, 11(23): 166-167. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA201623118.htm
[13]	张德智, 王璐瑶, 梁怀虹. 中晚期食管癌患者3D-CRT同步化疗的临床效果[J]. 中国实用医药, 2017, 12(3): 25-27. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA201703011.htm
[14]	张定富, 吴秋芳, 戈长征, 等. 顺铂联合5-FU化疗同步放疗治疗食管癌的临床效果[J]. 现代肿瘤医学, 2017, 25(13): 2061-2064. doi: 10.3969/j.issn.1672-4992.2017.13.013
[15]	戚诚, 赵晓东, 刘博, 等. 华蟾素胶囊联合同步放化疗治疗局部晚期食管癌的疗效分析[J]. 中国肿瘤临床与康复, 2017, 24(5): 525-528. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZK201705004.htm
[16]	范俊利, 雷彩鹏, 张卫国. 多烯紫杉醇联合奈达铂同步放化疗治疗局部中晚期食管癌疗效观察[J]. 哈尔滨医药, 2019, 39(6): 523-524. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYY201906011.htm
[17]	SONG T, ZHANG X B, FANG M, et al. Long-term results of definitive concurrent chemoradiotherapy using paclitaxel plus oxaliplatin in unresectable locally advanced esophageal cancer: A prospective phase Ⅱ trial[J]. Cancer Med, 2016, 5(12): 3371-3377. doi: 10.1002/cam4.897